W/F Red: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
Sarah Gomez (talk | contribs) |
Sarah Gomez (talk | contribs) |
||
| Line 1: | Line 1: | ||
== Wednesday/Friday Red Presentation Page == | == Wednesday/Friday Red Presentation Page == | ||
=== Overview === | === Overview === | ||
Our research aims to use gene therapy to mobilize bone marrow stem cells and RNAi to chemoattract the progenitor cells to damaged heart tissue with the goal of treating ischemic | Our research aims to use gene therapy to mobilize bone marrow stem cells and RNAi to chemoattract the progenitor cells to damaged heart tissue with the goal of treating ischemic cardiomyopathy. | ||
=== Background Research === | === Background Research === | ||
Revision as of 07:58, 4 May 2009
Wednesday/Friday Red Presentation Page
Overview
Our research aims to use gene therapy to mobilize bone marrow stem cells and RNAi to chemoattract the progenitor cells to damaged heart tissue with the goal of treating ischemic cardiomyopathy.
Background Research
Ischemic cardiomyopathy
Ischemic cardiomyopathy is a cause of congestive heart failure due to coronary artery disease. Ischemic refers the condition in which an organ does not obtain sufficent oxygen. Myopathy refers to a muscle related disease. Ischemic cardiomypoathy affects approximately 1 of 100 people in the United States.
Research Problem and Goals
Expected Results
Necessary Materials
Resources
- Zaruba, M-M. et al. "Synergy between CD26/DPP–IV inhibition and G–CSF improves cardiac function after acute myocardial infarction." Cell Stem Cell 4 313–323 (2009). http://www.ncbi.nlm.nih.gov/pubmed/19341621
- “Ischemic cardiomyopathy.” Medical Encyclopedia. 3 September 2008 http://www.nlm.nih.gov/medlineplus/ency/article/000160.htm
